The 125,000-square-foot facility, which is slated to be operational in 2027, is where cutting-edge genetic medicine will meet industrial scale, says CEO Chris Murphy.
The agreement supports development and clinical manufacturing of induced pluripotent stem cell-derived therapies targeting ocular and retinal diseases.
First announced in July 2025, the new Research Triangle Park site will provide formulation, analytical, and drug product development services for biopharma clients.
